Emcure Pharmaceutical posts 48% YoY jump in net profit; shares up nearly 2%

Shares of Emcure Pharmaceuticals rose nearly 2% on Wednesday afternoon amid a sharp rise in Q3FY26 net profit. The company’s shares traded 1.7% higher at ₹1,531 apiece on the NSE.

Emcure Pharmaceuticals on Wednesday posted a 48%YoY in its consolidated profit after tax at ₹231 crore for the third quarter ended December 31, 2025, led by robust sales growth in business verticals.

The drug firm reported a Profit After Tax (PAT) of ₹156 crore for the October-December period of the last fiscal. On the operational front, the company’s EBITDA (Earnings before interest, tax and depreciation) jumped 27% YoY to ₹460 crore as against ₹362 crore in the same period last year. Similarly, the operating margins also expanded nearly 100 points at 19.44% vs 18.47% in the Q3FY25.

Revenue from operations increased to ₹2,363 crore for the period under review as against ₹1,963 crore in the year-ago period, Emcure Pharmaceuticals said in a statement. Domestic business grew 15.4%, led by strong performance across all key therapies, especially chronic segments, including cardio/diabeto, and aided by new initiatives.

International business grew a healthy 24.5% with all geographies reporting strong performance. The rest of the World (RoW) business grew 30.7% led by strong performance in both non-ARV and ARV segments. Europe continues to see strong traction led by Manx and Amphotericin B rollout. Canada's business saw a robust growth of 12.8%.

Emcure Pharmaceuticals CEO and MD Satish Mehta said Q3 delivered a strong performance, with all its businesses outpacing industry growth.

“The company’s focus remains on improving profitability even as it continues to invest in people, products and processes to drive strong growth”, he added.

"The Novo Nordisk partnership has given Emcure an early-entry advantage, positioning us well in the fast-growing obesity segment. We remain focused on delivering strong growth along with margin improvement,” Mehta stated.

The company’s shares have rallied over 22% on 12-month basis and traded 9% up in 2026 till date.